PAREXEL® Access eHub:

Value Through Evidence

Back to Content Hub

How to increase the impact of observational research

Collating the right kind of economic data will make the most of late phase studies. Real-world analysis, conducted with an experienced late phase partner, will build a robust argument for reimbursement and help bring your new drug to market, faster.

Real data, such as actual costs when the drug is in use and the observed impact the product has on the quality of life for patients, is the late phase data payers want to see. 

For smooth pharmaceutical product development and effective market access strategy, you need a partner that offers an integrated solution for late phase clinical research, such as PAREXEL. 

Engaging one partner throughout the drug development process not only reduces costs over time, but increases accountability and commitment. 

Advanced Learnings From The Field

Share this: